Simon Cartmell has 24 years pharmaceutical, healthcare and biotechnology industry experience. He spent 17 years at GlaxoWellcome in a number of U.K. and global roles, including Therapy Area Director, Infectious Diseases and Hepatitis, with international research, development and commercial responsibility for this £1.8 billion business. Prior to this he was Customer Services and Supply Chain Director, responsible for the order fulfilment process from GW’s seven U.K. manufacturing sites. His initial experience was in the U.K. organisation in a variety of increasingly senior sales and marketing roles. Simon joined Vernalis plc (formerly Vanguard Medica plc) as Chief Operating Officer in 1998 overseeing its acquisition of Cerebrus plc in 1999. Following this he joined the main board of Celltech plc in the role of Chief Executive Officer for Celltech Pharmaceuticals in mid 2000, where he was responsible for the performance and future development of the global pharmaceuticals business, including supply operations.

More recently Simon has been interim CEO of Entomed sa, a Strasbourg based early stage biotech, where he remains a Non Executive Director. He is also Non Executive Chairman of Curidium Ltd, an advisor to a number of Venture and Private Equity groups and a Sloan Fellow from London Business School.